scholarly journals Safety and Efficacy Evaluation of Traditional Chinese Medicine (Qingre-Lishi-Yishen Formula) Based on Treatment of Regular Glucocorticoid Combined with Cyclophosphamide Pulse in Children Suffered from Moderately Severe Henoch–Schonlein Purpura Nephritis with Nephrotic Proteinuria

2020 ◽  
Vol 2020 ◽  
pp. 1-10 ◽  
Author(s):  
Lirong Fan ◽  
Huimin Yan ◽  
Xiaofang Zhen ◽  
Xiaoming Wu ◽  
Jing Hao ◽  
...  
Keyword(s):  
Therapeutic Regimen ◽  
Clinical Effects ◽  
Short Term ◽  
Efficacy Evaluation ◽  
Safety And Efficacy ◽  
Nephrotic Proteinuria ◽  
Cyclophosphamide Pulse ◽  
Schonlein Purpura ◽  
Purpura Nephritis

Objective. At present, the most appropriate management of Henoch–Schonlein purpura nephritis (HSPN) with nephrotic-range proteinuria still remains controversial; thus, the purpose of this study is to evaluate safety and efficacy of traditional Chinese medicine (TCM), Qingre-Lishi-Yishen Formula (QLYF), integrated with regular oral glucocorticoid and cyclophosphamide intravenous pulse therapeutic regimen in children suffered from moderately severe HSPN with nephrotic proteinuria. Methods. From 1 January 2012, to 1 January 2016, totally 150 hospitalized children suffered from HSPN with nephrotic proteinuria were included. All were treated with glucocorticoid and cyclophosphamide, and 100 of them were treated with integrative traditional Chinese decoction QLYF. Patients were followed up for 2 years. Rate of adverse event occurrence, short-term clinical effects, long-term clinical effects, and TCM therapeutic evaluation were all compared. Results. Total adverse event rate was lower in the QLYF group (χ2 = 5.357, p=0.022); rates of respiratory infection, urinary infection, poor appetite, hepatotoxity, cardiotoxicity, and neutropenia were all decreased in patients who received QLYF (p<0.05), and no cases of hepatic and renal toxicities related to the herbal medicine were observed in the QLYF group. For short-term clinical efficacy evaluation, lower levels of 24 hour proteinuria (p<0.05) and urine blood cell count (p<0.05) were found in the QLYF group. For long-term efficacy evaluation, better clinical control rate effective rate, lower recurrence rate (p<0.05), and fewer TCM syndrome score (p<0.05) were found in the QLYF group. Conclusion. Compared with merely using regular oral glucocorticoid plus cyclophosphamide pulse therapeutic regimen, the therapeutic regimen that integrates QLYF with the abovementioned western medicine might be a safe means to decrease the occurrence rate of adverse events and improve short-term and long-term clinical effects in children who suffered from moderately severe HSPN with nephrotic proteinuria.

scholarly journals Efficacy of Triptolide for Children with Moderately Severe Henoch-Schönlein Purpura Nephritis Presenting with Nephrotic Range Proteinuria: A Prospective and Controlled Study in China

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Li Wu ◽  
Jianhua Mao ◽  
Xia Jin ◽  
Haidong Fu ◽  
Huijun Shen ◽  
...  
Keyword(s):  
Treatment Group ◽  
Control Group ◽  
Henoch Schonlein Purpura ◽  
Short Term ◽  
Significant Difference ◽  
Schonlein Purpura ◽  
Nephrotic Range Proteinuria ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

Objective.To observe the clinical efficacy of the Chinese herb, Triptolide, in children with moderately severe Henoch-Schönlein purpura nephritis (HSPN).Methods. From January 2007 to December 2011, 56 HSPN children manifested by nephrotic range proteinuria with normal kidney function and<50% crescents or sclerosing lesions on biopsy were hospitalized in the Children’s Hospital of Zhejiang University School of Medicine. They were divided into two groups: the treatment group (Triptolide at a dosage of 1 mg/kg·d, combined with prednisone at a dosage of 2 mg/kg·d, within a course of medium-to-long-term therapy of 6 to 9 months) and the control group (; prednisone alone, with the same procedure).Results.Short-term remission was observed in 95% of patients from treatment group and in 72% of patients from control group, respectively. There was a significant difference between both groups () for short-term effects. Meanwhile, no significant difference, as proteinuria, hematuria, hypertension, and decreased eGFR, was observed between the two groups in long-term followup (). The Kaplan-Meier plot analysis also revealed no significant difference ().Conclusion.Triptolide is effective in relieving short-term symptoms for moderately severe HSPN children, though its long-term effects need to be observed further.

Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure

1999 ◽  
Vol 138 (2) ◽  
pp. 261-268 ◽  
Author(s):  
Marrick L. Kukin ◽  
Ronald S. Freudenberger ◽  
Michael M. Mannino ◽  
Jill Kalman ◽  
Marilyn Steinmetz ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Clinical Effects ◽  
Short Term

Long-term safety, tolerability, and efficacy of OROS® hydromorphone in patients with chronic pain

2018 ◽  
Vol 5 (2) ◽  
pp. 97 ◽  
Author(s):  
Mark Wallace, MD ◽  
Dwight E. Moulin, MD ◽  
Richard L. Rauck, MD ◽  
Sarita Khanna, PhD ◽  
Iulia Cristina Tudor, PhD ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Plasma Concentrations ◽  
Brief Pain Inventory ◽  
The United States ◽  
Short Term ◽  
Open Label ◽  
Safety And Efficacy ◽  
Analgesic Effects ◽  
N 93

Objective: To assess the safety and efficacy of long-term repeated dosing of OROS® hydromorphone in chronic pain patients.Design: This multicenter, open-label extension trial enrolled patients from three short-term OROS® hydromorphone trials.Setting: Fifty-six centers in the United States and Canada.Patients: Adults with chronic cancer pain or chronic nonmalignant pain who were receiving stable doses of OROS® hydromorphone (≥8 mg/day). Three hundred and eighty-eight patients were enrolled, 106 patients completed at least 12 months of therapy.Interventions: OROS® hydromorphone (individualized doses) was administered once daily.Main outcome measures: Safety and efficacy (Brief Pain Inventory and patient and investigator global evaluations) were assessed at monthly visits.Results: The median duration of extended OROS® hydromorphone therapy was 274 days. The median daily dose of study medication was 32.0 mg at extension-study baseline, 40.0 mg at month 3, and 48.0 mg at months 6, 9, and 12, respectively. The most frequently reported adverse events were nausea (n = 93, 24.0 percent) and constipation (n = 75, 19.3 percent). The analgesic effects of OROS® hydromorphone, assessed using the Brief Pain Inventory, were maintained throughout the extension. At 12 months, 72.4 percent of patients and 75.9 percent of investigators rated overall treatment as good, very good, or excellent.Conclusions: Once-daily OROS® hydromorphone is an osmotically driven, controlled-release preparation that may be particularly well suited to long-term use, because it provides consistent plasma concentrations and sustained around-the-clock analgesia. In this study, the benefits of OROS® hydromorphone attained in short-term studies were maintained in the long-term when daily administration was continued.

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation*

2007 ◽  
Vol 35 (6) ◽  
pp. 1457-1463 ◽  
Author(s):  
Pierre-Francois Laterre ◽  
Edward Abraham ◽  
Jonathan M. Janes ◽  
Benjamin L. Trzaskoma ◽  
Nancy L. Correll ◽  
...  
Keyword(s):  
Severe Sepsis ◽  
Drotrecogin Alfa ◽  
Early Stage ◽  
Efficacy Evaluation ◽  
Safety And Efficacy ◽  
Drotrecogin Alfa Activated ◽  
Long Term Follow Up ◽  
One Year

scholarly journals Short-term and Long-term Feasibility, Safety, and Efficacy of High-Intensity Interval Training in Cardiac Rehabilitation

2020 ◽  
Vol 5 (12) ◽  
pp. 1382
Author(s):  
Jenna L. Taylor ◽  
David J. Holland ◽  
Shelley E. Keating ◽  
Michael D. Leveritt ◽  
Sjaan R. Gomersall ◽  
...  
Keyword(s):  
Cardiac Rehabilitation ◽  
High Intensity ◽  
Interval Training ◽  
High Intensity Interval Training ◽  
Short Term ◽  
Safety And Efficacy ◽  
High Intensity Interval

Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression

2007 ◽  
Vol 22 (10) ◽  
pp. 1717-1722 ◽  
Author(s):  
Mohan Shenoy ◽  
Mark G. Bradbury ◽  
Malcolm A. Lewis ◽  
Nicholas J. A. Webb
Keyword(s):  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

Positive aspects, negative aspects and challenges associated with stem cell therapy for COVID - 19: A Mini-Review

2021 ◽  
Vol 16 ◽  
Author(s):  
Basavraj Nagoba ◽  
Ajay Gavkare ◽  
Abhijit Rayate ◽  
Sachin Mumbre
Keyword(s):  
Financial Constraints ◽  
Potential Role ◽  
Treatment Options ◽  
Short Term ◽  
Safety And Efficacy ◽  
Respiratory Involvement ◽  
Literature Reviews ◽  
Effective Option ◽  
Cytokine Imbalance

: Like any other pandemic, the Covid-19 scenario has also demanded effective treatment options. The circumstances demand to utilize all the possible weapons in the armamentarium. There have been many issues regarding the short-term and long-term safety and efficacy of these options. Some options are like uncharted seas and these need a detailed and critical review with respect to safety, efficacy, feasibility and financial constraints. Mesenchymal stem cells (MSCs) therapy has been studied for many years for its potential role in diseases with complex pathogenesis. Its efficacy in controlling cytokine imbalance and immuno-modulatory properties is well proven. These effects are being extensively studied for potential extension of the benefits for an effective option for management of COVID-19 patients with severe respiratory involvement. In this mini-review, an attempt has been made to review positive aspects, negative aspects, and challenges influencing MSCs therapy in the management of COVID-19 disease. The results of various studies and literature reviews show that MSCs therapy can be considered as one of the potential options.

Sign in / Sign up

Export Citation Format

Share Document